Spots Global Cancer Trial Database for Tolerability and Activity of Brivaracetam (BRV) in Patients With Diffuse Gliomas
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Tolerability and Activity of Brivaracetam (BRV) in Patients With Diffuse Gliomas
Official Title: Tolerability and Activity of Brivaracetam (BRV) in Patients With Diffuse Gliomas
Study ID: NCT05029960
Conditions
Interventions
Study Description
Brief Summary: The purpose of this study is to determine whether the study medication, brivaracetam, is tolerable and safe for patients with brain tumors.
Detailed Description: In this study, subjects will receive usual treatment for their brain tumor. In addition, they will be given brivaracetam at a dose of 50 mg twice daily.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
University of Rochester Medical Center, Rochester, New York, United States
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
